Traws Pharma (TRAW) announced the retirement of Werner Cautreels, CEO, effective on or about close of business on March 31 after the company files its annual report on Form 10-K with the SEC. Iain Dukes will assume the role of interim CEO. In addition to his new responsibilities, Dukes will continue to serve as Traws’ chairman.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRAW:
- Traws Pharma presents data on COVID-19 candidate ratutrelvir at ICAR
- Traws Pharma announces results from study of tivoxavir marboxil in bird flu
- Traws Pharma presents data on tivoxavir marboxil for bird flu treatment
- Traws Pharma reports results from bird flu model for tivoxavir marboxil
- Traws Pharma Regains Nasdaq Compliance with $20M Financing